These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18611220)

  • 21. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
    Du QS; Sun H; Chou KC
    Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.
    Berry M; Fielding BC; Gamieldien J
    Viruses; 2015 Dec; 7(12):6642-60. PubMed ID: 26694449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.
    Akaji K; Konno H; Mitsui H; Teruya K; Shimamoto Y; Hattori Y; Ozaki T; Kusunoki M; Sanjoh A
    J Med Chem; 2011 Dec; 54(23):7962-73. PubMed ID: 22014094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.
    Teruya K; Hattori Y; Shimamoto Y; Kobayashi K; Sanjoh A; Nakagawa A; Yamashita E; Akaji K
    Biopolymers; 2016 Nov; 106(4):391-403. PubMed ID: 26572934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
    Huitema C; Zhang J; Yin J; James MN; Vederas JC; Eltis LD
    Bioorg Med Chem; 2008 May; 16(10):5761-77. PubMed ID: 18407505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.
    Tan J; George S; Kusov Y; Perbandt M; Anemüller S; Mesters JR; Norder H; Coutard B; Lacroix C; Leyssen P; Neyts J; Hilgenfeld R
    J Virol; 2013 Apr; 87(8):4339-51. PubMed ID: 23388726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protease inhibitors broadly effective against feline, ferret and mink coronaviruses.
    Perera KD; Galasiti Kankanamalage AC; Rathnayake AD; Honeyfield A; Groutas W; Chang KO; Kim Y
    Antiviral Res; 2018 Dec; 160():79-86. PubMed ID: 30342822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.
    Liu YC; Huang V; Chao TC; Hsiao CD; Lin A; Chang MF; Chow LP
    Biochem Biophys Res Commun; 2005 Jul; 333(1):194-9. PubMed ID: 15950190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
    Pillaiyar T; Manickam M; Namasivayam V; Hayashi Y; Jung SH
    J Med Chem; 2016 Jul; 59(14):6595-628. PubMed ID: 26878082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.
    Konno H; Onuma T; Nitanai I; Wakabayashi M; Yano S; Teruya K; Akaji K
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2746-2751. PubMed ID: 28454669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The SARS-CoV-2 main protease (M
    Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB
    MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational and inhibitive analysis of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer-based assays.
    Kuang WF; Chow LP; Wu MH; Hwang LH
    Biochem Biophys Res Commun; 2005 Jun; 331(4):1554-9. PubMed ID: 15883050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease.
    Kim Y; Mandadapu SR; Groutas WC; Chang KO
    Antiviral Res; 2013 Feb; 97(2):161-8. PubMed ID: 23219425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.